CTA-101 is under clinical development by Nanjing Bioheng Biotech and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CTA-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CTA-101 overview
CTA-101 is under development for the treatment of relapsed or refractory diffuse large B-cell lymphoma, CD19+ acute B-lymphocytic leukemia, chronic lymphocytic leukemia, follicular lymphoma and primary mediastinal B-cell lymphoma . The therapy constitutes of adeno-associated virus (AAV) and genetically manipulated allogeneic T cells which express a universal chimeric antigen receptor (UCART) targeting cells expressing B lymphocyte antigen CD19 (CD-19). It is administered as intravenous infusion.
Nanjing Bioheng Biotech overview
Nanjing Bioheng Biotech Co., Ltd., is engaged in developing cell therapy products and universal CAR-T product. The company is headquartered in China.
For a complete picture of CTA-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
